Published
The committee will discuss new drug application (NDA) 216660, for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, submitted by Amylyx Pharmaceuticals Inc., for the treatment of amyotrophic lateral sclerosis (ALS).
- Category
- Health
Be the first to comment
-
57:48
AANP Teaching Rounds - September 27 - Infectious Diseases of the Central Nervous System
-
13:19
Alzheimer disease | CH-2(d) | L-3 | Pharmacotherapeutics |Central nervous system|D.Pharm second year
-
6:32:04
180th Meeting of Vaccines and Related Biological Products Advisory Committee
-
7:47:26
179th Meeting of Vaccines and Related Biological Products Advisory Committee - Day 1
-
8:27:00
176th Meeting of the Vaccines and Related Biological Products Advisory Committee
-
8:05:40
Makena Hearing involving the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee - Day 2
-
5:46:31
179th Meeting of Vaccines and Related Biological Products Advisory Committee
-
8:12:21
Meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC)
-
42:55
Infectious Diseases of the Central Nervous System: Characteristic Findings
-
00:40
#multiplesclerosis -A Disease of the Central Nervous system that is predominant in females
-
03:19
Jowar Khichdi Recipe | Healthy & Yummy | Gluten Free Weight Loss Millet Recipes | Culinary Aromas
-
08:07
৭ দিনে যৌন ক্ষমতা বাড়ানোর কুরআনী চিকিৎসা/ Treatment of metal corrosion disease in Bangla
-
00:12
Healthy Lifestyle
